ID | 117178 |
著者 |
Hayashi, Kenji
Hayashi Hospital
板東, 浩
Hayashi Hospital|Tokushima University|Japan Low Carbohydrate Diet Promotion Association
KAKEN研究者をさがす
Miki, Kazuya
Hayashi Hospital
Yasuoka, Eri
Hayashi Hospital
Kamoto, Asami
Hayashi Hospital
Yasuoka, Tatsuo
Hayashi Hospital
|
キーワード | Glucagon-like peptide 1 receptor agonist (GLP-1 RA)
semaglutide
Rybelsus
sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC)
bioavailability
|
資料タイプ |
学術雑誌論文
|
抄録 | Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been attracted attention for various beneficial effects. Among them, oral semaglutide (Rybelsus) was developed using the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). The relationship between the bioavailability and post-dose fasting time period was analyzed. The results showed that i) its bioavailability with drinking 50mL and 120mL of water together was almost similar, ii) bioavailability for 240mL intake was about 2/3 of 50-120mL, iii) general availability would be about 1.4% for 50-120ml water, and 0.8% for 240mL of water. Tolerability and safety of Rybelsus showed similar results for healthy subjects, patients with renal and/or hepatic impairment. From mentioned above, Rybelsus has been one of the topic agents with characteristic mechanism of SNAC and clinical benefit of GLP-1RA. It will be expected to be applied widely in actual diabetic practice.
|
掲載誌名 |
International Journal of Complementary & Alternative Medicine
|
ISSN | 23811803
|
出版者 | MedCrave Publishing
|
巻 | 15
|
号 | 3
|
開始ページ | 151
|
終了ページ | 152
|
発行日 | 2022-06-03
|
権利情報 | This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and build upon your work non-commercially.
|
出版社版DOI | |
出版社版URL | |
フルテキストファイル | |
言語 |
eng
|
著者版フラグ |
出版社版
|
部局 |
医学系
|